Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.

IF 3 4区医学 Q3 Biochemistry, Genetics and Molecular Biology

Hormones & Cancer Pub Date : 2019-06-01 DOI:10.1007/s12672-019-00363-4

Rita Indirli, Emanuele Ferrante, Elisa Sala, Claudia Giavoli, Giovanna Mantovani, Maura Arosio

{"title":"Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.","authors":"Rita Indirli, Emanuele Ferrante, Elisa Sala, Claudia Giavoli, Giovanna Mantovani, Maura Arosio","doi":"10.1007/s12672-019-00363-4","DOIUrl":null,"url":null,"abstract":"<p><p>Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (\"PRE\" group), while 14 after menopause (\"POST\" group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2-464.3 mIU/L) compared with those in long-term remission (94.3, 29.7-402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040-0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal's outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":"10 2-3","pages":"120-127"},"PeriodicalIF":3.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-019-00363-4","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-019-00363-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 7

Abstract

Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause ("PRE" group), while 14 after menopause ("POST" group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2-464.3 mIU/L) compared with those in long-term remission (94.3, 29.7-402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040-0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal's outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.

Abstract Image

查看原文本刊更多论文

绝经前后停用卡麦角林:微泌乳素瘤的预后。

绝经后催乳素瘤的自然病程尚未完全阐明。本研究的目的是比较卡麦角林停药后绝经前和绝经后微泌乳素瘤妇女的复发率。回顾性选择62例经卡麦角林治疗至少1年并停药后随访2年的微泌乳素瘤妇女。患者分为两组:绝经前停用卡麦角林48例(PRE组)，绝经后停用卡麦角林14例(POST组)。复发定义为催乳素水平高于正常，两次证实。总的来说，62名女性中有39名复发。复发患者停药前泌乳素水平明显高于长期缓解患者(94.3,29.7-402.8 mIU/L;p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormones & Cancer ONCOLOGY-ENDOCRINOLOGY & METABOLISM

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.